The Pharma Team's Real Guide to AI-Generated Synthetic Health Data
What AI-generated synthetic health data actually is
A high-fidelity synthetic medical dataset is not a spreadsheet of fictional patients invented by an algorithm. It is the output of a generative model — a synthetic data generator healthcare teams deploy — typically a Generative Adversarial Network (GAN) — trained on real patient records to produce a synthetic EHR dataset reflecting the statistical structure of the source population.
The model learns: how often hypertension co-occurs with type 2 diabetes in patients over 65. What a realistic sequence of second-line oncology treatments looks like. How lab values at month three correlate with lab values at month twelve. The demographic distributions across a condition's patient population.
Then it generates new records — thousands or millions of them — that faithfully reflect those learned patterns. What it does not generate is any real patient's record. There is no individual in the synthetic dataset who corresponds to a real person.
This is the distinction that matters. The privacy protection is structural, not procedural. You are not removing identifying information from real data. The synthetic patient records generated are not derived from any real individual. You are generating data from a model that never outputs real data in the first place.
The mathematical privacy guarantee
If you want to know how private a synthetic dataset really is, the answer is a parameter called epsilon (ε) — the privacy budget in differential privacy.
Differential privacy provides a formal mathematical bound on the maximum information leakage about any individual in the training data. Applied through a mechanism called DP-SGD (Differentially Private Stochastic Gradient Descent) during GAN training, it ensures that the presence or absence of any single patient's records has only bounded influence on the trained model's outputs.
The smaller ε is, the stronger the privacy guarantee — and the more the statistical fidelity of the output degrades. An ε of 1 provides near-ironclad privacy protection. An ε of 10 provides meaningful but modest protection. An ε above 10 is generally not meaningful enough to call privacy-preserving for sensitive health data.
The ε you should accept from a vendor depends on: the sensitivity of the source data, the intended distribution of the synthetic output, the jurisdiction you're operating in, and the size of the training dataset. It is not a technical parameter to be set in isolation — it requires a documented privacy impact assessment.
Three use cases where synthetic data genuinely wins
I want to be direct here: synthetic data in healthcare is not a universal solution. It has a bounded set of use cases where it genuinely outperforms alternatives, and a clearly defined set of use cases where it should not be used. Starting with the wins:
Rare disease data augmentation. This is the most compelling current use case and the one with the strongest methodological basis. For conditions affecting fewer than 1 in 2,000 people, real-world datasets are structurally too thin for stable ML model training, meaningful subgroup analysis, or propensity-score matched comparisons. Conditional GAN-based oversampling can augment rare disease cohorts in ways that improve analytical robustness — provided the synthetic rare-class records are validated for clinical plausibility.
Cross-border European data sharing. Synthetic data generation healthcare teams rely on most urgently is often this one. This is the use case that organisations underestimate most consistently. Patient-level data from national health systems in France, Germany, Sweden, Italy — it cannot be freely exported under GDPR and national health data laws. Federated analysis solves some of this. But true data integration across countries — combining patient cohorts, harmonising coding systems, running unified analytical models — requires either complex data transfer agreements or synthetic data generated locally that contains no real patient records. The synthetic data approach is often faster, cheaper, and legally cleaner.
ML training pipelines. Training AI-based clinical decision support tools — the core application of synthetic data in machine learning for medicine and healthcare — requires large, diverse, labelled datasets. Synthetic data can be scaled to arbitrary size, generated with controlled demographic distributions for bias testing, and produced with known ground-truth labels for supervised learning. For healthcare AI development, this is increasingly standard practice.
Three places synthetic data fails
Causal inference. This is the most important limitation and the most frequently misunderstood. A GAN trained on observational data learns and reproduces the statistical associations in that data — including all the confounding, selection bias, and indication bias present in the real-world dataset. Generating synthetic data from a confounded observational source does not remove the confounding. It faithfully reproduces it. If you cannot make a causal claim from the real data, you cannot make that claim from the synthetic data derived from it.
Primary regulatory submissions. As of 2026, no major regulatory agency — FDA, EMA, MHRA — accepts AI-generated synthetic health data as the primary evidence source for a regulatory submission. Synthetic data may support, supplement, or augment real-world evidence. It cannot substitute for it as the primary basis for safety or efficacy claims. Anyone telling you otherwise is ahead of where the guidance currently sits.
Rare safety signal detection. GAN mode collapse — a failure mode where the generator converges on common outputs and under-represents rare ones — disproportionately affects the exact adverse events that pharmacovigilance needs to detect. An event occurring at 1 in 10,000 rates may be statistically absent from a synthetic dataset even when present in the training data. Pharmacovigilance is not a valid synthetic data use case with current methods.
What regulators actually say
The FDA's most advanced acceptance of synthetic data is in the medical device pathway — CDRH explicitly permits synthetic data as training and testing data for AI/ML-based medical devices. For drug development, synthetic data is accepted for trial simulation, sensitivity analyses, and rare disease external control arm contexts — but not as primary evidence.
The EMA is actively piloting synthetic data under its DARWIN EU programme, primarily for cross-border data sharing solutions under GDPR constraints.
The ceiling is real — and it is also moving. Organisations building validation infrastructure and regulatory documentation practices now will be better positioned as guidance evolves.
The validation you cannot skip
Before any synthetic health dataset is used for analysis, three categories of validation are required — and all three must pass.
Statistical fidelity: Do the synthetic data's statistical properties match the real data? Measured via Jensen-Shannon divergence (target below 0.05 per variable), pairwise correlation differences (mean absolute difference below 0.10), and discriminator AUC from a trained classifier trying to distinguish real from synthetic (target below 0.60).
Analytical utility: Does a model trained on synthetic data and tested on real data perform comparably to a model trained on real data? The Train-on-Synthetic, Test-on-Real (TSTR) paradigm quantifies this. For RWE applications, validate that estimated effect measures are within pre-specified equivalence margins of those from real data.
Privacy: Do adversarial membership inference attacks confirm that no real record can be recovered from the synthetic dataset? Theoretical DP guarantees must be confirmed empirically through adversarial testing.
One more thing: validation is use-case specific. A dataset validated for ML model training is not validated for causal effect estimation. Document the validated uses explicitly. Prohibit use outside those boundaries.
The practical starting point
For most pharmaceutical organisations in 2026, the right entry point is not a large-scale synthetic data programme or an enterprise synthetic healthcare data platform. It is a bounded pilot in one clearly appropriate use case — rare disease augmentation, cross-border data integration, or ML pipeline development — that simultaneously builds the internal validation methodology, governance framework, and technical expertise on which broader deployment depends.
The "made-up data" objection has a precise, technical answer. Synthetic data healthcare critics who rely on this framing are conflating statistical generation with fabrication. A synthetic healthcare database generated by a GAN trained with differential privacy, validated across fidelity, utility, and privacy dimensions, and used within its validated use case boundaries, is not made-up data. It is statistically faithful, mathematically privacy-preserving, and fit for the specific purposes it has been validated for.
That is not a marketing claim. It is a methodological description. And it deserves to be understood on those terms.
The author writes on real-world evidence methodology and data strategy for pharmaceutical organisations. MEDDDICAL is a Pan-European RWE advisory service. More at
MEDDDICAL
City: Sotogrande
Address: Aptos 221
Website: https://medddical.com
Comments
Post a Comment